Dupilumab Approved for Eczema for Children 6 Months to 5 Years Dupilumab Approved for Eczema for Children 6 Months to 5 Years

The approval makes dupilumab the first biologic available in the United States to treat uncontrolled moderate-to-severe atopic dermatitis in this age group.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news